Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2018 | Ibrutinib plus obinutuzumab/venetoclax in R/R MCL: OAsIs results

Simon Rule • 18 Dec 2018
ASH 2018
Lymphoma Mantle Cell Lymphoma Non-Hodgkin Lymphoma Ibrutinib Obinutuzumab Venetoclax
OAsIs

Drug resistance in mantle cell lymphoma (MCL) is highly dependent on BCR signaling and the microenvironment. Here, Simon Rule, MD, of Plymouth University, Plymouth, UK, discusses the OAsIs Phase I trial (NCT02558816), which was designed to assess the safety, tolerability and efficacy of ibrutinib/obinutuzumab, and ibrutinib plus obinutuzumab/venetoclax, with hopes to tackle this resistance in relapsed/refractory MCL. Speaking from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Prof. Rule reveals that as well as having no dose-limiting toxicities, treatment was well tolerated and provided a high level of disease control.

More from Simon Rule

0:48
Real-world results in the UK for ibrutinib at first relapsed for MCL
Simon Rule • 7 Dec 2019
1:30
OAsIs trial update: ibrutinib, venetoclax plus obinutuzumab in newly diagnosed MCL
Simon Rule • 7 Dec 2019
1:28
Impressive results for R-BAC post BTKi in R/R MCL
Simon Rule • 7 Dec 2019
1:35
Long-term ibrutinib outcomes vs. prior regimens: pooled analysis in R/R MCL
Simon Rule • 6 Dec 2019

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals